Want to take quizzes and track your credits?
Can loop-mediated isothermal amplification (LAMP)-based methodology coupled with smartphone detection provide an inexpensive, rapid, sensitive, and reliable platform for COVID-19 and influenza testing?
In this cohort study of saliva samples from 50 community-based patients, the smartphone-based LAMP assay detected SARS-CoV-2 infection and exhibited concordance with reverse transcriptase–quantitative polymerase chain reaction tests.
These findings suggest that the smartphone-based LAMP assay offers an additional tool to detect COVID-19 that can be readily modified in response to novel SARS-CoV-2 variants and other pathogens with pandemic potential including influenza.
A critical need exists in low-income and middle-income countries for low-cost, low-tech, yet highly reliable and scalable testing for SARS-CoV-2 virus that is robust against circulating variants.
To assess whether a smartphone-based assay is suitable for SARS-CoV-2 and influenza virus testing without requiring specialized equipment, accessory devices, or custom reagents.
Design, Setting, and Participants
This cohort study enrolled 2 subgroups of participants (symptomatic and asymptomatic) at Santa Barbara Cottage Hospital. The symptomatic group consisted of 20 recruited patients who tested positive for SARS-CoV-2 with symptoms; 30 asymptomatic patients were recruited from the same community, through negative admission screening tests for SARS-CoV-2. The smartphone-based real-time loop-mediated isothermal amplification (smaRT-LAMP) was first optimized for analysis of human saliva samples spiked with either SARS-CoV-2 or influenza A or B virus; these results then were compared with those obtained by side-by-side analysis of spiked samples using the Centers for Disease Control and Prevention (CDC) criterion-standard reverse transcriptase–quantitative polymerase chain reaction (RT-qPCR) assay. Next, both assays were used to test for SARS-CoV-2 and influenza viruses present in blinded clinical saliva samples obtained from 50 hospitalized patients. Statistical analysis was performed from May to June 2021.
Testing for SARS-CoV-2 and influenza A and B viruses.
Main Outcomes and Measures
SARS-CoV-2 and influenza infection status and quantitative viral load were determined.
Among the 50 eligible participants with no prior SARS-CoV-2 infection included in the study, 29 were men. The mean age was 57 years (range, 21 to 93 years). SmaRT-LAMP exhibited 100% concordance (50 of 50 patient samples) with the CDC criterion-standard diagnostic for SARS-CoV-2 sensitivity (20 of 20 positive and 30 of 30 negative) and for quantitative detection of viral load. This platform also met the CDC criterion standard for detection of clinically similar influenza A and B viruses in spiked saliva samples (n = 20), and in saliva samples from hospitalized patients (50 of 50 negative). The smartphone-based LAMP assay was rapid (25 minutes), sensitive (1000 copies/mL), low-cost (<$7/test), and scalable (96 samples/phone).
Conclusions and Relevance
In this cohort study of saliva samples from patients, the smartphone-based LAMP assay detected SARS-CoV-2 infection and exhibited concordance with RT-qPCR tests. These findings suggest that this tool could be adapted in response to novel CoV-2 variants and other pathogens with pandemic potential including influenza and may be useful in settings with limited resources.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: December 3, 2021.
Published: January 28, 2022. doi:10.1001/jamanetworkopen.2021.45669
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Heithoff DM et al. JAMA Network Open.
Corresponding Author: Michael J. Mahan, PhD, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, 2119 Biological Sciences II, Santa Barbara, CA 93106 (email@example.com).
Author Contributions: Dr M. Mahan had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Heithoff, Barnes, S. Mahan, Fox, Ettinger, Fitzgibbons, Fried, Low, Samuel, M. Mahan.
Acquisition, analysis, or interpretation of data: Heithoff, Barnes, S. Mahan, Arn, Ettinger, Bishop, Fitzgibbons, Fried, Low, Samuel, M. Mahan.
Drafting of the manuscript: Heithoff, Barnes, S. Mahan, Ettinger, Fried, Low, Samuel, M. Mahan.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Heithoff, Fox, Arn, M. Mahan.
Obtained funding: M. Mahan.
Administrative, technical, or material support: Heithoff, Barnes, S. Mahan, Fox, Ettinger, Fitzgibbons, Fried, Low, Samuel, M. Mahan.
Supervision: Heithoff, Fitzgibbons, Fried, Low, Samuel, M. Mahan.
Conflict of Interest Disclosures: None reported.
Funding/Support: This research was funded by National Institutes of Health (NIH) HL131474 (Drs Fried and M. Mahan), Cottage Health Research Institute (Drs Low and M. Mahan), and U.S. Army Research Office via the Institute for Collaborative Biotechnologies cooperative agreement W911NF-19-2-0026 (Dr M. Mahan) and contract W911NF-19-D-0001-0013 (Drs Low and M. Mahan).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We would like to thank Ken Y. Yoneda, MD, Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California Davis, for helpful insights regarding patient study design; compensation was not received for this work.
You currently have no searches saved.
You currently have no courses saved.